Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568607 | 1.00 | NAALAD2 (0.49) | NAALAD2ALDH1A1FPR2ASAH1ACER2 | |
| SCHEMBL23886710 | 0.90 | NAALAD2 (0.51) | NAALAD2ALDH1A1FPR2ATMMEN1 | |
| SCHEMBL23886709 | 0.90 | NAALAD2 (0.51) | NAALAD2ALDH1A1FPR2ATMMEN1 | |
| SCHEMBL30831553 | 0.85 | NAALAD2 (0.50) | NAALAD2ALDH1A1FPR2ASAH1ACER2 | |
| SCHEMBL15063201 | 0.84 | NAALAD2 (0.49) | NAALAD2ALDH1A1FPR2ASAH1ACER2 | |
| SCHEMBL11265966 | 0.83 | FPR2 (0.51) | NAALAD2ALDH1A1FPR2ATMMEN1 | |
| SCHEMBL31043495 | 0.83 | ASAH1 (0.63) | ALDH1A1ASAH1ACER2NPSR1UGCG | |
| SCHEMBL31043494 | 0.83 | ASAH1 (0.63) | ALDH1A1ASAH1ACER2NPSR1UGCG | |
| SCHEMBL9150499 | 0.82 | ASAH1 (0.46) | ALDH1A1ASAH1ACER2MAPTUGCG | |
| SCHEMBL22207714 | 0.81 | NAALAD2 (0.60) | NAALAD2ALDH1A1FPR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | NAALAD2 1279/4885ALDH1A1 4027/4885FPR2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.